EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials

Cho-Han Chiang, Yu-Cheng Chang, Chun-Chiao Yu, Xin Ya See, Tsu Hsien Wang, Nutchapon Xanthavanij, Junmin Song, Shao-Wei Lo, Cho-Hung Chiang, Leslie Lake, Mandy N Lauw, Kenneth A Bauer und 2 weitere

Journal of Thrombosis and Haemostasis · 2025-11 · 23 (11) · 3527-3539

DOI: 10.1016/j.jtha.2025.06.020 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025-11. Verfasst von Cho-Han Chiang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Incretins. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Conquer Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Obesity is an established risk factor for venous thromboembolism (VTE). Observational data suggest that glucagon-like peptide 1 receptor agonists (GLP-1RAs) may reduce the risk of VTE. However, the effects of GLP-1RAs on VTE have not been tested in randomized controlled trials (RCTs). OBJECTIVES: To investigate the impact of GLP-1RAs on VTE risk using data from RCTs. METHODS: We conducted a systematic review and meta-analysis of placebo-controlled RCTs focusing on GLP-1RA use in patients with type 2 diabetes mellitus (T2DM) or obesity. Five databases were searched from inception to October 2024. The primary outcome was VTE, which was a composite of pulmonary embolism (PE), deep vein thrombosis, and VTE at other sites, and the secondary outcomes were the individual events. RESULTS: Twenty-seven RCTs with 84 003 patients were analyzed. The median incidence of VTE was 1.1 and 2.5 per 1000 patient-years in the GLP-1RA and placebo groups, respectively. There was no statistically significant difference in overall VTE risk between GLP-1RA and placebo groups (risk ratio [RR], 0.70; 95% CI, 0.46-1.07). However, GLP-1RAs were associated with a significantly lower risk of PE (RR, 0.60; 95% CI, 0.39-0.94). In contrast, there were no significant differences in the risk of deep vein thrombosis (RR, 1.21; 95% CI, 0.69-2.12) or VTE at other sites (RR, 0.56; 95% CI, 0.25-1.26). CONCLUSION: In this meta-analysis of randomized trials, GLP-1RAs were not associated with a significant reduction in overall VTE risk but were associated with a lower risk of PE among patients with T2DM or obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsIncretinsObesityVenous ThromboembolismFemaleHumansMaleMiddle AgedIncidencePulmonary EmbolismRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsTreatment OutcomeVenous Thrombosis

Stichwörter der Autor:innen

glucagon-like peptide 1 receptor agonistspulmonary embolismvenous thromboembolism

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsIncretins

Autor:innen und Institutionen

  • Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, Massachusetts, USA.
  • Department of Medicine, Danbury Hospital, Danbury, Connecticut, USA.
  • School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Department of Medicine, Unity Hospital, Rochester Regional Health, Rochester, New York, USA.
  • Department of Medicine, University at Buffalo-Catholic Health System, Buffalo, New York, USA.
  • Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.

Förderung

  • Conquer Cancer Foundation

Zitieren

APA

Chiang, C. H., Chang, Y. C., Yu, C. C., See, X. Y., Wang, T. H., Xanthavanij, N., Song, J., Lo, S. W., Chiang, C. H., Lake, L., Lauw, M. N., Bauer, K. A., Kazi, D. S., & Patell, R. (2025). Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials. Journal of Thrombosis and Haemostasis, 23(11), 3527-3539. https://doi.org/10.1016/j.jtha.2025.06.020

Vancouver

Chiang CH, Chang YC, Yu CC, See XY, Wang TH, Xanthavanij N, et al. Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials. Journal of Thrombosis and Haemostasis. 2025;23(11):3527-3539. doi:10.1016/j.jtha.2025.06.020

BibTeX
@article{Chiang2025,
  author = {Chiang, Cho-Han and Chang, Yu-Cheng and Yu, Chun-Chiao and See, Xin Ya and Wang, Tsu Hsien and Xanthavanij, Nutchapon and Song, Junmin and Lo, Shao-Wei and Chiang, Cho-Hung and Lake, Leslie and Lauw, Mandy N and Bauer, Kenneth A and Kazi, Dhruv S and Patell, Rushad},
  title = {Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  volume = {23},
  number = {11},
  pages = {3527--3539},
  doi = {10.1016/j.jtha.2025.06.020}
}
Kostenlos starten →